Cue Biopharma, Inc. (CUE)

Market Cap	78.90M
Revenue (ttm)	11.68M
Net Income (ttm)	-48.84M
Shares Out	35.38M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	110,501
Open	2.35
Previous Close	2.39
Day's Range	2.20 - 2.45
52-Week Range	2.20 - 18.42
Beta	1.66
Analysts	Buy
Price Target	11.90 (+433.6%)
Earnings Date	Nov 7, 2022

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-1...

• Industry: Biotechnology
• IPO Date: Jan 2, 2018
• CEO: Daniel Passeri
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: CUE

Full Company Profile

Financial Performance

In 2021, Cue Biopharma's revenue was $14.94 million, an increase of 373.68% compared to the previous year's $3.15 million. Losses were -$44.16 million, -1.39% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CUE stock is "Buy." The 12-month stock price forecast is 11.9, which is an increase of 433.63% from the latest price.

Price Target

$11.9

(433.63% upside)

Analyst Consensus: Buy

Stock Forecasts